Pharmaceuticals

With a new U.S. patent, Quoin Pharmaceuticals reinforces its strategy for QRX003, a potential first-ever treatment for devastating Netherton Syndrome.

As demand for its blockbuster drugs soars, Novo Nordisk turns to India's Shantha Biologics in a strategic deal that highlights a global supply chain shift.

New Phase 1 data suggests vamorolone delivers potent anti-inflammatory effects without the severe immunosuppression of traditional steroids at clinical doses.

Following a $103M funding round, Kinaset Therapeutics adds proven dealmakers to its board, signaling a strategic push for its novel inhaled asthma therapy.

Vistagen's Phase 3 trial for its novel anxiety nasal spray fails its main goal, but a surprising signal in severe cases prompts a high-stakes pivot.

Will Therapeutics lands $3.5M to develop the first targeted drug for anorexia, aiming to treat the biological roots of compulsion. A breakthrough in the making?

Biotech firm R1 Therapeutics forms a star-studded advisory board to guide its promising kidney disease drug, AP306, into crucial Phase 2b trials.

Interim data for Pasithea Therapeutics' PAS-004 shows durable activity and superior safety, offering a new strategy for patients who have run out of options.

Positive Phase 3 data for BRUKINSA shows a 43% reduction in cancer progression, heralding a chemotherapy-free future for frontline mantle cell lymphoma.

Cytonics completes a key safety trial for its novel osteoarthritis drug, CYT-108. But the real story is a masterclass in strategic innovation.

With Olav Hellebø at the helm, Exonate is advancing a topical eye drop that could end painful eye injections for millions with diabetic retinopathy.

With a fresh €6.3M, Munich-based smartbax is developing antibiotics that make bacteria self-destruct, offering new hope against a growing global crisis.

New data on at-home lecanemab injections signals a major shift in Alzheimer's care, promising greater convenience and access for patients and caregivers.

A new partnership between Finland's Orion Pharma and India's Shilpa Medicare aims to bring a lower-cost cancer therapy to Europe, challenging a blockbuster drug.

With FDA Priority Review for its at-home therapy Enspryng, Roche is signaling a major disruption in the lucrative Thyroid Eye Disease market.

Health Canada's approval of a generic Wegovy promises to slash costs and expand access, shifting the landscape for patients and the healthcare system.

A new chemo-free combo from Genmab and AbbVie shows a 60% reduction in disease progression for a tough-to-treat blood cancer, setting a new standard.

With FDA clearance, Gain Therapeutics' GT-02287, an AI-discovered drug, advances to Phase 2, offering a new hope to modify Parkinson's, not just its symptoms.

After a fierce campaign reversed drastic cuts to Florida's HIV drug program, thousands can breathe again. But a new cap and missing aid reveal a fragile victory.